Heart Transplant Failure and Rejection Clinical Trial
Official title:
Impact of Donor and Recipient ST2 / IL-33 Pathway on Recipient Survival and Acute Rejection After Heart Transplantation
Evaluate the association between donor soluble protein ST2 (sST2) serum levels and 30-day recipient mortality in order to improve graft screening.
Soluble protein sST2 has recently become a prognostic biomarker in the context of acute
myocardial infarction and chronic heart failure, and recent studies also show that sST2 is
involved in acute rejection of the cardiac graft in recipients. Experimental studies confirm
that the ST2 / IL-33 pathway is involved in the process leading to cardiac transplant
rejection in animals. In particular, administration of IL-33 would have a positive effect on
pre-clinical cardiac graft survival. No study have looked at the level of ST2 / IL-33 of the
donor, with the purpose that it might reflect the condition of the transplanted heart and
its initial level of Immune tolerance and maybe predict the risk of subsequent dysfunction.
In this non-interventional study, several blood samples will be taken on donors before organ
procurement and on recipients prior to grafting, on day 7 and at the time of each myocardial
biopsy (approximately 16 myocardial biopsies the first year). Serum level of sST2 and IL-33
will then be determined according to the ELISA method on each blood sample.
Fifty consecutive couple donors/ recipients will be included in the study. This number of
subjects is calculated to detect a doubling of the donor sST2 level between the two
recipient groups with 30-day mortality and without mortality (potency: 90%, alpha risk:
0.05, bilateral).
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03102125 -
Allograft Dysfunction in Heart Transplant
|
Phase 4 | |
| Active, not recruiting |
NCT04380311 -
Precision Guided Tacrolimus Dosing in Pediatric Heart Transplant
|
N/A | |
| Completed |
NCT02109575 -
Quantitative Detection of Circulating Donor-Specific DNA in Organ Transplant Recipients (DTRT-Multi-Center Study)
|
||
| Not yet recruiting |
NCT06414603 -
A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy
|
N/A | |
| Completed |
NCT04610320 -
Daratumumab-SC for Highly Sensitized Patients Awaiting Heart Transplantation
|
Phase 1 | |
| Active, not recruiting |
NCT03386539 -
Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score
|
Phase 3 | |
| Withdrawn |
NCT05081739 -
Donor-Derived Cell-free DNA to DETect REjection in Cardiac Transplantation
|
N/A | |
| Recruiting |
NCT03499197 -
Heart TIMING - Heart Transplantation IMagING
|
||
| Recruiting |
NCT03538509 -
Percutaneous Coronary Intervention in Patients witH OrthotoPic hEart Transplantation: the PCI-HOPE a Multicenter Study.
|
||
| Active, not recruiting |
NCT03373279 -
Bioelectrical Impedance Spectroscopy in Heart Transplantation: Tracking Post-Transplant Changes in Body Composition and Correlation With Conventional Preoperative Risk Assessment Modalities
|
||
| Recruiting |
NCT05994274 -
A Clinical Study of Association Between Postoperative Dyslipidemia and Organ Rejection in Transplant Patients
|
||
| Active, not recruiting |
NCT03575910 -
HEARTBiT: Multi-Marker Blood Test for Acute Cardiac Transplant Rejection
|
||
| Not yet recruiting |
NCT06453148 -
Brazilian Clinical Registry of Heart Transplantation
|
||
| Withdrawn |
NCT04088903 -
Study of Daratumumab for Decreasing Circulating Antibodies in Sensitized Patients Awaiting Heart Transplantation
|
Phase 1 |